Astonea Labs Ltd Stock Price Today (NSE: ASTONEALAB)
Fundamental Score
Astonea Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Astonea Labs Ltd share price today is ₹255.20, down 4.88% on NSE/BSE as of 17 June 2026. Astonea Labs Ltd (ASTONEALAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹157.67 (Cr). The 52-week high for ASTONEALAB share price is ₹273.95 and the 52-week low is ₹118.00. At a P/E ratio of 33.98x, ASTONEALAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 44.66% and a debt-to-equity ratio of 0.73.
Astonea Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Astonea Labs Ltd share price chart: 44.51% return over the past month. 52-week high ₹273.95, 52-week low ₹118.00.
Astonea Labs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹237.00 | ₹273.95 | ₹237.00 | ₹273.95 | 15.00K (Cr) | |
| ₹232.00 | ₹238.00 | ₹230.55 | ₹238.00 | 11.00K (Cr) | |
| ₹229.00 | ₹231.00 | ₹229.00 | ₹230.55 | 6.00K (Cr) | |
| ₹234.95 | ₹234.95 | ₹226.10 | ₹230.50 | 19.00K (Cr) | |
| ₹230.10 | ₹233.10 | ₹229.00 | ₹229.00 | 26.00K (Cr) | |
| ₹230.00 | ₹235.95 | ₹217.00 | ₹231.00 | 28.00K (Cr) | |
| ₹200.00 | ₹228.00 | ₹200.00 | ₹227.00 | 22.00K (Cr) | |
| ₹185.00 | ₹198.00 | ₹185.00 | ₹197.65 | 13.00K (Cr) | |
| ₹185.00 | ₹185.00 | ₹185.00 | ₹185.00 | 2.00K (Cr) | |
| ₹182.95 | ₹183.00 | ₹182.00 | ₹182.00 | 4.00K (Cr) |
Astonea Labs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹232.00 | ₹273.95 | ₹230.55 | ₹273.95 | +18.08% | |
| ₹160.00 | ₹235.95 | ₹130.05 | ₹230.55 | +44.09% | |
| ₹150.00 | ₹165.00 | ₹150.00 | ₹160.05 | +6.70% | |
| ₹158.50 | ₹159.50 | ₹145.00 | ₹153.10 | -3.41% | |
| ₹152.50 | ₹160.00 | ₹151.50 | ₹158.50 | +3.93% | |
| ₹154.00 | ₹160.00 | ₹150.00 | ₹156.00 | +1.30% | |
| ₹150.20 | ₹163.95 | ₹137.00 | ₹163.50 | +8.85% | |
| ₹150.00 | ₹161.95 | ₹118.00 | ₹150.00 | +0.00% | |
| ₹164.90 | ₹165.00 | ₹138.05 | ₹150.00 | -9.04% | |
| ₹173.55 | ₹180.00 | ₹161.00 | ₹161.00 | -7.23% | |
| ₹169.95 | ₹183.40 | ₹146.15 | ₹174.80 | +2.85% | |
| ₹148.50 | ₹185.00 | ₹143.00 | ₹164.15 | +10.54% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Astonea Labs is a micro-cap play fueled by related party transactions, making it a governance risk with limited organic growth.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Astonea Labs completed the acquisition of a 25.74% stake in Damaira Pharmaceuticals for , utilizing reallocated IPO proceeds. This acquisition was approved at an Extraordinary General Meeting (EGM) on March 27, 2026, where shareholders also approved material related party transactions worth for FY 2026-27.
CORE STORY (THE REAL GAME)
- Completed Damaira Pharma acquisition for ₹6.25 crore
- Approved ₹415 crore in related party transactions for FY27
- Shareholders approved new Articles of Association
- Successful integration of Damaira Pharma
- Significant order wins outside of related party transactions
- Improved quarterly earnings demonstrating organic growth
- Micro/SME cap exposes to liquidity risk
- Heavy reliance on related party transactions raises governance concerns
- YoY Profit down -33.33%
FII and DII have decreased their holdings by 5.5% and 4.2% respectively.
Indian pharmaceutical exports are growing, but US Pharma Tariff 2026 is a potential headwind.
Astonea Labs completed the acquisition of a 25.74% stake in Damaira Pharmaceuticals for ₹6.25 crore.
No Free Cash Flow data available.
Astonea's future hinges on successful integration of Damaira and the ability to generate organic growth beyond related party transactions. Expect volatility due to micro-cap nature.
Primary Thesis Risk
Over-reliance on related party transactions poses a significant governance risk and limits organic growth potential.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Astonea Labs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Astonea Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ASTONEALAB across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Return on Equity (44.66%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (19.74%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Revenue Growth (40.24%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (72.30%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Profit Decline Concern (-33.33%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 2.86%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Astonea Labs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Astonea Labs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Astonea Labs LtdAstonea Labs Lt...Selected✓ ASTONEALAB • 544409 | 31.6/100 | ₹255.20₹255 | ₹157.67₹157.67 | 33.98Average 34.0 Average | 44.66%Excellent 44.66% Excellent | 19.74%Good 19.74% Good | 0.73Good 0.7 Good | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Astonea Labs Ltd Quarterly Performance
Latest quarterly metrics for ASTONEALAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
40.24%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-33.33%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Astonea Labs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ASTONEALAB — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Astonea Labs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Astonea Labs Ltd (ASTONEALAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Astonea Labs Ltd
About ASTONEALAB (Astonea Labs Ltd)
Astonea Labs Ltd is a dynamic pharmaceutical company dedicated to improving global health and well-being through the development, manufacturing, and distribution of high-quality ph...armaceutical and cosmetic products. Driven by innovation and a commitment to excellence, ASTONEALAB meticulously formulates and produces a diverse portfolio of medicines and personal care solutions designed to meet the evolving needs of patients and consumers worldwide. Our unwavering focus on research and development ensures that we remain at the forefront of scientific advancements, constantly exploring new therapeutic possibilities and pushing the boundaries of product efficacy and safety. ASTONEALAB strives to be a trusted partner for healthcare professionals and individuals seeking reliable and effective solutions for a healthier and more vibrant life. ASTONEALAB's product range encompasses a broad spectrum of therapeutic areas, addressing various health concerns and enhancing the quality of life. We offer a comprehensive selection of pharmaceutical products, including essential generic medications, over-the-counter remedies, specialized therapies targeting specific conditions, and innovative nutraceuticals designed to support overall wellness. Furthermore, ASTONEALAB's commitment to beauty and personal care is reflected in our extensive line of cosmetic products, which includes advanced skincare formulas, revitalizing haircare solutions, and age-defying treatments. Our dedication to quality extends across all product categories, ensuring that every item bearing the ASTONEALAB name meets the highest standards of purity, potency, and efficacy. ASTONEALAB operates with a global vision, extending its reach to serve diverse markets and communities around the world. We are committed to fostering strong partnerships with healthcare providers, distributors, and other stakeholders to ensure that our products are readily accessible to those who need them most. Through strategic collaborations and a robust distribution network, ASTONEALAB is expanding its presence in both established and emerging markets, bringing innovative healthcare solutions to a wider audience. We remain steadfast in our mission to make a positive impact on the health and well-being of individuals and communities worldwide, guided by our core values of integrity, innovation, and unwavering commitment to quality.
Company Details
Key Leadership
ASTONEALAB Share Price: Frequently Asked Questions
What is the current share price of Astonea Labs Ltd?
Astonea Labs Ltd (ASTONEALAB) trades at ₹255.20 on NSE and BSE. Market cap ₹157.67 (Cr). Educational data only.
What is the P/E ratio of Astonea Labs Ltd?
Astonea Labs Ltd has a P/E of 33.98x vs industry average 31.77x.
What is the Bull Run score for Astonea Labs Ltd?
Astonea Labs Ltd has a Bull Run score of 31.6/100 based on 25+ financial parameters.
Does Astonea Labs Ltd pay dividends?
Astonea Labs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Astonea Labs Ltd?
Astonea Labs Ltd has ROE of 44.66%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Astonea Labs Ltd?
Astonea Labs Ltd has debt-to-equity of 0.73.
Is Astonea Labs Ltd a good investment?
Bull Run gives Astonea Labs Ltd a score of 31.6/100. This is not investment advice — consult a SEBI-registered advisor.